Table 2.

Cardiac medications and clinical outcomes of patients with cardiotoxic events

Patient	Cancer	Treatment	Cardiac medications	Cardiotoxic event	Clinical outcomes
Patient 1	Esophageal adenocarcinoma	5‐FU	Statin	Chest pain, troponin elevation, ischemic ECG changes, reduced ejection fraction	Discontinued 5‐FU; started on carboplatin, paclitaxel, trastuzumab
Patient 2	Rectal adenocarcinoma	5‐FU	Aspirin, Calcium channel blocker, Nitrates	Chest pain	Discontinued 5‐FU; no further treatment
Patient 3	Rectal adenocarcinoma	Capecitabine	None	Chest pain, troponin elevation, ischemic ECG changes, reduced ejection fraction	Discontinued capecitabine; no further treatment
Patient 4	Pancreatic ductal adenocarcinoma	Capecitabine	Aspirin, calcium channel blocker	Chest pain	Continued capecitabine
Patient 5	Pancreatic ductal adenocarcinoma	5‐FU	Aspirin, statin, calcium channel blocker, nitrates	Chest pain	Continued 5‐FU
Patient 6	Pancreatic ductal adenocarcinoma	5‐FU	Aspirin, statin	Chest pain	Continued 5‐FU
Patient 7	Colon adenocarcinoma	5‐FU	Aspirin, statin, calcium channel blocker	Chest pain, ischemic ECG changes	Discontinued 5‐FU; started on carboplatin, paclitaxel
Patient 8	Pancreatic ductal adenocarcinoma	5‐FU	Statin, calcium channel blocker	Chest pain, troponin elevation	Continued 5‐FU

Abbreviations: 5‐FU, 5‐fluorouracil; ECG, echocardiogram.